Expertise in
7
conditions

Dr. Lori J. Goldstein

Oncology | Transplant Surgery
333 Cottman Ave, Fox Chase Cancer Center, 
Philadelphia, PA 
Expertise in
7
conditions
333 Cottman Ave, Fox Chase Cancer Center, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lori Goldstein is an Oncologist and a Transplant Surgeon in Philadelphia, Pennsylvania. Dr. Goldstein is highly rated in 7 conditions, according to our data. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Tissue Biopsy.

Her clinical research consists of co-authoring 112 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Transplant Surgery
Licenses
Pharmacist in NJ
Specialist in PA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

333 Cottman Ave, Fox Chase Cancer Center, Philadelphia, PA 19111
Other Locations
35 Longwood Rd, Middle Island, NY 11953
19638 Star Island Dr, Boca Raton, FL 33498
403 Heartwood Rd, Cherry Hill, NJ 08003

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
Enrollment Status: Completed
Publish Date: September 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

112 Total Publications

Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.
Journal: Journal of the National Cancer Institute
Published: August 22, 2024
Similar Doctors
Expertise in
18
conditions
Dr. Daniel M. Geynisman
Oncology | Transplant Surgery
Expertise in
18
conditions
Dr. Daniel M. Geynisman
Oncology | Transplant Surgery

Temple Faculty Practice Plan Inc

3401 N Broad St, 
Philadelphia, PA 
 (5.5 miles away)
215-707-5030
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Geynisman is an Oncologist and a Transplant Surgeon in Philadelphia, Pennsylvania. Dr. Geynisman is highly rated in 18 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Urothelial Cancer, and Nephrectomy.

Expertise in
15
conditions
Dr. Elizabeth R. Plimack
Oncology | Transplant Surgery
Expertise in
15
conditions
Dr. Elizabeth R. Plimack
Oncology | Transplant Surgery

Temple Faculty Practice Plan Inc

3401 N Broad St, 
Philadelphia, PA 
 (5.5 miles away)
215-707-5030
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elizabeth Plimack is an Oncologist and a Transplant Surgeon in Philadelphia, Pennsylvania. Dr. Plimack is highly rated in 15 conditions, according to our data. Her top areas of expertise are Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy.

Anthony J. Olszanski
Expertise in
15
conditions
Dr. Anthony J. Olszanski
Oncology | Transplant Surgery
Expertise in
15
conditions
Dr. Anthony J. Olszanski
Oncology | Transplant Surgery

Temple Faculty Practice Plan Inc

3401 N Broad St, 
Philadelphia, PA 
 (5.5 miles away)
215-707-5030
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony Olszanski is an Oncologist and a Transplant Surgeon in Philadelphia, Pennsylvania. Dr. Olszanski is highly rated in 15 conditions, according to our data. His top areas of expertise are Melanoma, Pleuropulmonary Blastoma, Lung Adenocarcinoma, and ALK-Positive Non-Small Cell Lung Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goldstein's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile